Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide

Cancer Immunology Research

Volumn 3, Issue 4, 2015, Pages 320-325

  Mitchell, Duane A ^a   Sayour, Elias J ^a   Reap, Elizabeth ^b   Schmittling, Robert ^b   De Leon, Gabriel ^a   Norberg, Pamela ^b   Desjardins, Annick ^b   Friedman, Allan H ^b   Friedman, Henry S ^b   Archer, Gary ^b   Sampson, John H ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; SARGRAMOSTIM; TEMOZOLOMIDE; ALKYLATING AGENT; AUTOANTIBODY; CANCER VACCINE; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ADULT; ALLERGIC REACTION; ANTIBODY DETECTION; ARTICLE; BLOOD CELL COUNT; BURNING SENSATION; CASE REPORT; CAUCASIAN; CHEMORADIOTHERAPY; CONFUSION; CONJUNCTIVITIS; CRANIOTOMY; DIAPHORESIS; DIZZINESS; DRUG DOSE INTENSIFICATION; EOSINOPHIL COUNT; FLUSHING; GLIOBLASTOMA; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMORAL IMMUNITY; IMMUNOREACTIVITY; INGUINAL REGION; INJECTION SITE INDURATION; INJECTION SITE SWELLING; LEUKAPHERESIS; LEUKOCYTE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PAPULAR RASH; PERIPHERAL BLOOD MONONUCLEAR CELL; SENSITIZATION; SIDE EFFECT; TELECONSULTATION; THROMBOCYTE COUNT; URTICARIA; VACCINATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DENDRITIC CELL; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; TRANSPLANTATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; AUTOANTIBODIES; CANCER VACCINES; COMBINED MODALITY THERAPY; DACARBAZINE; DENDRITIC CELLS; GLIOBLASTOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED;

EID: 84962256116     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0100     Document Type: Article

References (25)

1. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-7.
2. Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol 2013;9:977-90.
3. Johnson LA, Sampson JH. Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep 2010;10:259-66.
4. Mitchell DA, Sampson JH. Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics 2009;6:527-38.
5. Mitchell DA, Archer G, Bigner D, Friedman H, Lally-Goss D, Perry B, et al. Dendritic cell vaccines targeting human cytomegalovirus in glioblastoma reveal lymph node homing as a major axis for clinical intervention. Neurooncol 2012;14:47.
6. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 2008;359: 539-41.
7. Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong LY, Wu A, et al. Gliomaassociated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res 2011;17:4642-9.
8. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011;30: 150-82.
9. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother 2012;35:159-68.
10. Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. Thedetection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol 2011;103:231-8.
11. Batich K, Snyder D, Xie WH, Reap E, Archer G, Sampson J, et al. Enhancement of dendritic cell migration to vaccine-site draining lymph nodes as a means to generate potent anti-tumor immune responses. Neuro-oncol 2012;14:41.
12. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, Yun CO. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther 2011;19:1558-68.
13. Eksioglu EA, Kielbasa J, Eisen S, Reddy V. Granulocyte-macrophage colonystimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation. Cytotherapy 2011;13:888-96.
14. Cobbs CS Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol 2013;25:682-8.
15. Nair SK, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J, et al. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res 2014;20:2684-94.
16. Chang HR, Cordon-Cardo C, Houghton AN, Cheung NK, Brennan MF. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 1992;70:633-8.
17. Reap EA, Dryga SA, Morris J, Rivers B, Norberg PK, Olmsted RA, et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol 2007;14:748-55.
18. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:1738-44.
19. Huizar I, Kavuru MS. Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Curr Opin Pulm Med 2009;15:491-8.
20. Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE, et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009;113: 2547-56.
21. Shahar E, Krivoy N, Pollack S. Effective acute desensitization for immediate-type hypersensitivity to human granulocyte-monocyte colony stimulating factor. Ann Allergy Asthma Immunol 1999;83:543-6.
22. Stone HD Jr, DiPiro C, Davis PC, Meyer CF, Wray BB. Hypersensitivity reactions to Escherichia coli-derived polyethylene glycolated-asparaginase associated with subsequent immediate skin test reactivity to E. coli-derived granulocyte colony-stimulating factor. J Allergy Clin Immunol 1998;101: 429-31.
23. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003;2:278-99.
24. Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev 2013;34:15-38.
25. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy 2007;37:989-99.